Serinus Biosciences GTM brain

Serinus Biosciences develops computationally informed therapeutics and seeks biopharma co-development partners.

market profile

text: The YC description focuses on rational cancer combinations that address treatment resistance, and invites drug co-development.
text: Its LinkedIn now describes molecular glue therapeutics for oncology and immunology, so current program focus needs verification.

title: Oncology discovery or translational research leader
pains:
- Tumors can evolve resistance to a treatment
- Finding combinations with a defensible biological rationale consumes research resources
title: Biopharma business development director
pains:
- Needs differentiated programs and credible co-development partners
- Must assess experimental evidence, intellectual property and deal terms

text: Therapeutics companies with oncology programs and a need for combination discovery are potential collaborators; company size and deal terms are unspecified.
text: Academic cancer and systems biology researchers are plausible collaborators where resistance mechanisms need experimental validation.

objection: Do predicted combinations have experimental or clinical support?
response: Review target-specific validation and development stage; model predictions do not establish clinical efficacy.
objection: Who owns resulting intellectual property?
response: Discuss rights, milestones and program scope directly because public deal terms are unavailable.

name: Lantern Pharma
why: Listed as an AI oncology drug discovery competitor, with a broader oncology focus.
name: Insilico Medicine
why: Develops AI-enabled drug discovery programs and competes for pharma R&D partnerships.

text: A drug developer is investigating resistance to an existing oncology asset and seeking combinations.
text: A biopharma discovery team is looking for hard-to-drug oncology or immunology targets.

model: unknown

unknown

low

name: Adam Yaari
title: Founder/CEO
role: CEO
bio: Prior to founding Serinus, Adam gained over 10 years of entrepreneurship experience including a Microsoft R&D Fellowship and Flagship Pioneering Ideation Fellowship. Adam is passionate about developing advanced AI models for biological research that will bring medicine to scale. Adam received his PhD and MS in computer science from MIT, MSc in computer science and mathematics from the Weizmann Institute of Science, and dual major BSc in computer science and neuroscience from Bar-Ilan University.
name: Maxwell Sherman
title: Founder/CTO
role: CTO
bio: After five years as a paramedic, Max left clinical medicine to develop new treatments for the millions of patients without access to effective medications. He studied applied math and biology at Brown University, statistics at Cambridge University, and is completing his PhD in computational biology at MIT. His research has appeared in prestigious journals including Science, Nature Biotechnology, and Nature Neuroscience and has been recognized with national and international awards.